» Articles » PMID: 38051885

Rethinking Neurodegenerative Diseases: Neurometabolic Concept Linking Lipid Oxidation to Diseases in the Central Nervous System

Abstract

Currently, there is a lack of effective medicines capable of halting or reversing the progression of neurodegenerative disorders, including amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, or Alzheimer's disease. Given the unmet medical need, it is necessary to reevaluate the existing paradigms of how to target these diseases. When considering neurodegenerative diseases from a systemic neurometabolic perspective, it becomes possible to explain the shared pathological features. This innovative approach presented in this paper draws upon extensive research conducted by the authors and researchers worldwide. In this review, we highlight the importance of metabolic mitochondrial dysfunction in the context of neurodegenerative diseases. We provide an overview of the risk factors associated with developing neurodegenerative disorders, including genetic, epigenetic, and environmental factors. Additionally, we examine pathological mechanisms implicated in these diseases such as oxidative stress, accumulation of misfolded proteins, inflammation, demyelination, death of neurons, insulin resistance, dysbiosis, and neurotransmitter disturbances. Finally, we outline a proposal for the restoration of mitochondrial metabolism, a crucial aspect that may hold the key to facilitating curative therapeutic interventions for neurodegenerative disorders in forthcoming advancements.

Citing Articles

Transcriptome Study of rd1Mouse Brain and Association with Parkinson's Disease.

Zhou Y, Yang Y, Qi T, Hou Z, Ge Q, Lu Z ACS Omega. 2024; 9(24):25756-25765.

PMID: 38911794 PMC: 11191077. DOI: 10.1021/acsomega.3c09938.


In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route.

Ghosh A, Majie A, Karmakar V, Chatterjee K, Chakraborty S, Pandey M AAPS PharmSciTech. 2024; 25(5):96.

PMID: 38710855 DOI: 10.1208/s12249-024-02810-0.

References
1.
Zhang S, Gui L, Liu Y, Shi S, Cheng Y . Oxidative Stress Marker Aberrations in Multiple Sclerosis: A Meta-Analysis Study. Front Neurosci. 2020; 14:823. PMC: 7479227. DOI: 10.3389/fnins.2020.00823. View

2.
Trabjerg M, Andersen D, Huntjens P, Mork K, Warming N, Kullab U . Inhibition of carnitine palmitoyl-transferase 1 is a potential target in a mouse model of Parkinson's disease. NPJ Parkinsons Dis. 2023; 9(1):6. PMC: 9867753. DOI: 10.1038/s41531-023-00450-y. View

3.
Pineda-Torra I, Siddique S, Waddington K, Farrell R, Jury E . Disrupted Lipid Metabolism in Multiple Sclerosis: A Role for Liver X Receptors?. Front Endocrinol (Lausanne). 2021; 12:639757. PMC: 8076792. DOI: 10.3389/fendo.2021.639757. View

4.
Chen Z, Zhong C . Oxidative stress in Alzheimer's disease. Neurosci Bull. 2014; 30(2):271-81. PMC: 5562667. DOI: 10.1007/s12264-013-1423-y. View

5.
Gratacos-Batlle E, Olivella M, Sanchez-Fernandez N, Yefimenko N, Miguez-Cabello F, Fado R . Mechanisms of CPT1C-Dependent AMPAR Trafficking Enhancement. Front Mol Neurosci. 2018; 11:275. PMC: 6092487. DOI: 10.3389/fnmol.2018.00275. View